These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38468291)

  • 1. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments.
    Chen T; Deng J; Zhang Y; Liu B; Liu R; Zhu Y; Zhou M; Lin Y; Xia B; Lin K; Ma X; Zhang H
    Mol Cancer; 2024 Mar; 23(1):53. PubMed ID: 38468291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
    Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
    Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens.
    Akatsuka Y
    Front Immunol; 2020; 11():257. PubMed ID: 32184779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
    Lau E; Kwong G; Fowler TW; Sun BC; Donohoue PD; Davis RT; Bryan M; McCawley S; Clarke SC; Williams C; Banh L; Irby M; Edwards L; Storlie M; Kohrs B; Lilley GWJ; Smith SC; Gradia S; Fuller CK; Skoble J; Garner E; van Overbeek M; Kanner SB
    Cytotherapy; 2023 Jul; 25(7):750-762. PubMed ID: 37086241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
    Michaux A; Mauën S; Breman E; Dheur MS; Twyffels L; Saerens L; Jacques-Hespel C; Gauthy E; Agaugué S; Gilham DE; Sotiropoulou PA
    J Immunother; 2022 Apr; 45(3):150-161. PubMed ID: 35191428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
    Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
    Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient derivation of chimeric-antigen receptor-modified T
    Kranz E; Kuhlmann CJ; Chan J; Kim PY; Chen ISY; Kamata M
    Front Immunol; 2022; 13():877682. PubMed ID: 35967430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
    Sutherland AR; Owens MN; Geyer CR
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.